Table 4.
Association of Percent Density with Risk of Breast Cancer for the BI-RADS, CM and ABDM Method* Contralateral Side↑,‡
| BI-RADS | CM (PD) | ABDM (PDA) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Category | Case/ Control |
OR (95%) | AUC | View | Quartile PD or PDA§,‖ |
Case/ Control |
OR (95%) | AUC | Case/ Control |
OR (95%) | AUC |
| 1 | 92/254 | 1.00 (reference) | 0.61 | CC | 1 | 56/175 | 1.00 (reference) | 0.63 | 41/178 | 1.00 (reference) | 0.64 |
| 2 | 43/78 | 1.58 (1.01–2.48) | 2 | 87/176 | 1.69 (1.13–2.53) | 81/172 | 2.31 (1.47–3.64) | ||||
| 3 | 86/182 | 1.49 (1.04–2.14) | 3 | 90/176 | 2.10 (1.37–3.22) | 100/178 | 3.02 (1.94–4.70) | ||||
| 4 | 148/198 | 2.61 (1.82–3.75) | 4 | 130/176 | 3.81 (2.42–5.99) | 141/175 | 5.18 (3.26–8.20) | ||||
| Continuous** | 1.67 (1.42–1.97) | 0.64 | 1.79 (1.53–2.10) | 0.64 | |||||||
| MLO | 1 | 57/175 | 1.00 (reference) | 0.60 | 36/175 | 1.00 (reference) | 0.64 | ||||
| 2 | 98/178 | 1.83 (1.23–2.74) | 75/179 | 2.53 (1.56–4.10) | |||||||
| 3 | 96/175 | 2.00 (1.32–3.05) | 114/179 | 4.48 (2.76–7.27) | |||||||
| 4 | 113/179 | 2.82 (1.81–4.40) | 139/174 | 6.14 (3.74–10.08) | |||||||
| Continuous** | 1.56 (1.33–1.83) | 0.63 | 1.89 (1.61–2.23) | 0.64 | |||||||
All models were adjusted for age and body mass index.
For all models, p-values from tests for trend were < 0.001.
Numbers of cases and controls are the same for analyses of PD and PDA performed within CC (363 cases, 703 controls) and MLO (364 cases, 707 controls) views. Numbers of cases and controls for BI-RADS analyses were 369 cases and 712 controls.
Cutpoints for quartiles of CM percent density (PD) for craniocaudal (CC) view are 15.8, 25.8, 35.6 and for mediolateral oblique (MLO) view are 14.5, 23.7, 32.7.
Cutpoints for quartiles for ABDM percent density (PDA) for CC view are 15.4, 20.1, 23.9 and for MLO view are 15.7, 19.4, 23.0.
Continuous PD and PDA assessments correspond to a one standard deviation increase. SDs are 14.6 and 13.5 for PD from CC and MLO views and 5.5 and 5.1 for PDA from CC and MLOs.